Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cell Therapeutics
Data from CT-2106 clinical trial presented at ASCO
July 4th, 2006
At the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO), preliminary data from Cell Therapeutics, Inc.'s (CTI) (CTIC; MTAX) Phase I study of CT-2106, a novel polyglutamate-camptothecin conjugate for patients with advanced solid tumor malignancies, were presented. The study showed that dosing weekly for three consecutive weeks every 28 days resulted in a dose intensity similar to that seen with dosing once every 21 days. In the 19 patients studied, CT-2106 was generally well-tolerated, without the toxicities normally associated with camptothecin (CPT), specifically hemorrhagic cystitis and severe diarrhea. The maximum tolerated dose (MTD) was 25-35...
Source: Pharma Law Weekly (2006-07-04)
|
